Hansa Biopharma (LSE:0RC7) - Stock Price, News & Analysis

0RC7 Stock Overview

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States.

About the company

0RC7 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Revenue is forecast to grow 41.79% per year

Risk Analysis

Negative shareholders equity

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Hansa Biopharma AB (publ) Competitors

Avacta Group

AIM:AVCT

UK£126.9m

Oxford Biomedica

LSE:OXB

UK£212.5m

Destiny Pharma

AIM:DEST

UK£21.9m

Bioventix

AIM:BVXP

UK£236.2m

Price History & Performance

Summary of all time highs, changes and price drops for Hansa Biopharma
Historical stock prices
Current Share Price	kr29.56
52 Week High	kr57.30
52 Week Low	kr20.74
Beta	1.26
1 Month Change	1.36%
3 Month Change	-1.82%
1 Year Change	-37.27%
3 Year Change	-82.66%
5 Year Change	-83.74%
Change since IPO	-28.40%

Recent updates

Shareholder Returns

	0RC7	GB Biotechs	GB Market
7D	-0.006%	-1.9%	-0.9%
1Y	-37.3%	-30.5%	-1.8%

Return vs Industry: 0RC7 underperformed the UK Biotechs industry which returned -30.5% over the past year.

Return vs Market: 0RC7 underperformed the UK Market which returned -1.8% over the past year.

Price Volatility

Is 0RC7's price volatile compared to industry and market?
0RC7 volatility
0RC7 Average Weekly Movement	8.6%
Biotechs Industry Average Movement	7.4%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0RC7's share price has been volatile over the past 3 months.

Volatility Over Time: 0RC7's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
2007	166	Søren Tulstrup	www.hansabiopharma.com

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy.

Hansa Biopharma AB (publ) Fundamentals Summary

How do Hansa Biopharma's earnings and revenue compare to its market cap?
0RC7 fundamental statistics
Market cap	kr1.55b
Earnings (TTM)	-kr844.88m
Revenue (TTM)	kr165.88m

9.3x

P/S Ratio

-1.8x

P/E Ratio

Is 0RC7 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0RC7 income statement (TTM)
Revenue	kr165.88m
Cost of Revenue	kr71.66m
Gross Profit	kr94.23m
Other Expenses	kr939.10m
Earnings	-kr844.88m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 18, 2024

Earnings per share (EPS)	-15.35
Gross Margin	56.80%
Net Profit Margin	-509.33%
Debt/Equity Ratio	-247.8%

How did 0RC7 perform over the long term?

See historical performance and comparison

0RC7 Stock Overview

Rewards

Risk Analysis

Hansa Biopharma AB (publ) Competitors

AIM:AVCT

UK£126.9m

LSE:OXB

UK£212.5m

AIM:DEST

UK£21.9m

AIM:BVXP

UK£236.2m

Price History & Performance

Recent News & Updates

New minor risk - Shareholder dilution

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 372.1536 million.

Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022)

Hansa Biopharma AB (Publ) Announces CFO Changes

No longer forecast to breakeven

Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022)

Recent updates

New minor risk - Shareholder dilution

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 372.1536 million.

Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022)

Hansa Biopharma AB (Publ) Announces CFO Changes

No longer forecast to breakeven

Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022)

Hansa Biopharma AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Forecast to breakeven in 2026

Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation

Hansa Biopharma Nomination Committee Formed

President & CEO recently bought kr115k worth of stock

Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Third quarter 2023 earnings released: kr4.78 loss per share (vs kr3.45 loss in 3Q 2022)

New minor risk - Profitability

New minor risk - Profitability

Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma, Effective 1 December 2023

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma

Hansa Biopharma AB (publ) to Report Q1, 2024 Results on Apr 17, 2024

Hansa Biopharma Announces First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 Study in Anca-Associated Vasculitis

Second quarter 2023 earnings released: kr4.79 loss per share (vs kr3.82 loss in 2Q 2022)

Hansa Biopharma Receives Provisionally Approval in Australia as Desensitization Treatment in Highly Sensitized Patients Prior to Kidney Transplantation

New minor risk - Share price stability

Hansa Biopharma Announces First Patient Dosed with Imlifidase in a Global Pivotal Phase 3 Trial in Anti-Inaugular Basement Membrane (anti-GBM) Disease

First quarter 2023 earnings released: kr3.92 loss per share (vs kr3.11 loss in 1Q 2022)

Full year 2022 earnings released: kr13.57 loss per share (vs kr12.33 loss in FY 2021)

Hansa Biopharma Announces Planned Departure of Chief Scientific Officer Christian Kjellman

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma AB (publ) Announces Formation of Nomination Committee

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering.

Hansa Biopharma AB (Publ) Announces Positive Reimbursement Decision in Italy for Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation

Hansa Biopharma AB Announces Positive Topline Data from the Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study with Imlifidase as A Pre-Treatment to Sarepta's SRP-9001 Gene Therapy in DMD in 2023

Third quarter 2022 earnings released: kr3.45 loss per share (vs kr3.34 loss in 3Q 2021)

Hansa Biopharma AB (publ) to Report First Half, 2023 Results on Jul 20, 2023

The Scottish Medicines Consortium Recommends Use of Hansa Biopharma's Idefirix[®] (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix in Highly Sensitized Kidney Transplant Patients

Second quarter 2022 earnings released: kr3.82 loss per share (vs kr2.98 loss in 2Q 2021)

Hansa Biopharma AB (publ) announced that it has received $70 million in funding from NovaQuest Capital Management, L.L.C.

Hansa Biopharma Announces First Patient Treated in the Post-Authorization Efficacy Study (PAES) of Idefirix® (Imlifidase) in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Appoints Peter Nicklin as A New Member of the Board of Director

Senior VP recently bought kr346k worth of stock

NICE Recommends Use of Hansa Biopharma's Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Announces Ulf Wiinberg Not to Stand for Re-Election as Director

Hansa Biopharma Completes Enrollment in Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma Announces Temporary Marketing Authorization in Switzerland for Idefirix (Imlifidase) in Kidney Transplantation

Insider recently bought kr58k worth of stock

First quarter 2022 earnings released: kr3.11 loss per share (vs kr2.34 loss in 1Q 2021)

Hansa Biopharma Announces U.S. Fda Acceptance of Investigational New Drug (Ind) Application for Phase 3 Study of Imlifidase in Anti-Gbm Disease

Full year 2021 earnings released: kr12.33 loss per share (vs kr9.98 loss in FY 2020)

Hansa Biopharma AB and Medison Pharma Announces Marketing Authorization in Israel for Idefirix for Desensitization Treatment of Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB Announces Grant of Early Access Post Marketing Authorization for its First-In-Class Treatment Idefirix® (imlifidase)